Prostate Undifferentiated Carcinoma
NCI Definition: An invasive prostate carcinoma characterized by the presence of undifferentiated malignant cells. 
There are 2 clinical trials for prostate undifferentiated carcinoma, of which 2 are open and 0 are completed or closed. Of the trials that contain prostate undifferentiated carcinoma as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open).
ERBB2 is the most frequent gene inclusion criterion for prostate undifferentiated carcinoma clinical trials .
Trx518, abiraterone, and avelumab are the most common interventions in prostate undifferentiated carcinoma clinical trials.
Significant Genes in Prostate Undifferentiated Carcinoma
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for prostate undifferentiated carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and prostate undifferentiated carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.